Literature DB >> 26787701

Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication.

Daniel Todt1, Catherine François2, Patrick Behrendt3, Michael Engelmann1, Leonard Knegendorf1, Gabrielle Vieyres1, Heiner Wedemeyer4, Rune Hartmann5, Thomas Pietschmann1, Gilles Duverlie2, Eike Steinmann6.   

Abstract

Hepatitis E virus (HEV) is the causative agent of hepatitis E in humans and a member of the genusOrthohepevirusin the familyHepeviridae HEV infections are the common cause of acute hepatitis but can also take chronic courses. Ribavirin is the treatment of choice for most patients, and type I interferon (IFN) has been evaluated in a few infected transplant patientsin vivo In this study, the antiviral effects of different exogenously administered interferons were investigated by using state-of-the-art subgenomic replicon and full-length HEV genome cell culture models. Hepatitis C virus (HCV) subgenomic replicons based on the genotype 2a JFH1 isolate served as the reference. The experiments revealed that HEV RNA replication was inhibited by the application of all types of IFN, including IFN-α (type I), IFN-γ (type II), and IFN-λ3 (type III), but to a far lesser extent than HCV replication. Simultaneous determination of interferon-stimulated gene (ISG) expression levels for all IFN types demonstrated efficient downregulation by HEV. Furthermore, different IFN-α subtypes were also able to block viral replication in combination with ribavirin. The IFN-α subtypes 2a and 2b exerted the strongest antiviral activity against HEV. In conclusion, these data demonstrate for the first time moderate anti-HEV activities of types II and III IFNs and different IFN-α subtypes. As HEV employed a potent anti-interferon mechanism by restricting ISG expression, exogenous application of IFNs as immunotherapy should be carefully assessed.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26787701      PMCID: PMC4808167          DOI: 10.1128/AAC.02427-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

Review 1.  Pathogenesis and treatment of hepatitis e virus infection.

Authors:  Heiner Wedemeyer; Sven Pischke; Michael P Manns
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

2.  Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway.

Authors:  Xinying Zhou; Yijin Wang; Herold J Metselaar; Harry L A Janssen; Maikel P Peppelenbosch; Qiuwei Pan
Journal:  J Hepatol       Date:  2014-05-22       Impact factor: 25.083

3.  IRF9 is a key factor for eliciting the antiproliferative activity of IFN-alpha.

Authors:  Takaya Tsuno; Josef Mejido; Tongmao Zhao; Hana Schmeisser; Angel Morrow; Kathryn C Zoon
Journal:  J Immunother       Date:  2009-10       Impact factor: 4.456

4.  Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection.

Authors:  Nassim Kamar; Lionel Rostaing; Florence Abravanel; Cyril Garrouste; Sebastien Lhomme; Laure Esposito; Grégoire Basse; Olivier Cointault; David Ribes; Marie Béatrice Nogier; Laurent Alric; Jean Marie Peron; Jacques Izopet
Journal:  Gastroenterology       Date:  2010-08-11       Impact factor: 22.682

5.  Epigenetic silencing of CRABP2 and MX1 in head and neck tumors.

Authors:  Marilia F Calmon; Rodrigo V Rodrigues; Carla M Kaneto; Ricardo P Moura; Sabrina D Silva; Louise Danielle C Mota; Daniel G Pinheiro; Cesar Torres; Alex F de Carvalho; Patrícia M Cury; Fabio D Nunes; Ines Nobuko Nishimoto; Fernando A Soares; Adriana M A da Silva; Luis P Kowalski; Helena Brentani; Cleslei F Zanelli; Wilson A Silva; Paula Rahal; Eloiza H Tajara; Dirce M Carraro; Anamaria A Camargo; Sandro R Valentini
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

6.  Human interferon-lambda3 is a potent member of the type III interferon family.

Authors:  C Dellgren; H H Gad; O J Hamming; J Melchjorsen; R Hartmann
Journal:  Genes Immun       Date:  2008-11-06       Impact factor: 2.676

7.  Hepatitis E virus inhibits type I interferon induction by ORF1 products.

Authors:  Yuchen Nan; Ying Yu; Zexu Ma; Sunil K Khattar; Brenda Fredericksen; Yan-Jin Zhang
Journal:  J Virol       Date:  2014-08-06       Impact factor: 5.103

Review 8.  The impact of hepatitis E in the liver transplant setting.

Authors:  Patrick Behrendt; Eike Steinmann; Michael P Manns; Heiner Wedemeyer
Journal:  J Hepatol       Date:  2014-09-06       Impact factor: 25.083

9.  Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection.

Authors:  Kathrin Gibbert; Jara J Joedicke; Andreas Meryk; Mirko Trilling; Sandra Francois; Janine Duppach; Anke Kraft; Karl S Lang; Ulf Dittmer
Journal:  PLoS Pathog       Date:  2012-08-09       Impact factor: 6.823

Review 10.  Antiviral strategies for hepatitis E virus.

Authors:  Yannick Debing; Johan Neyts
Journal:  Antiviral Res       Date:  2013-12-25       Impact factor: 5.970

View more
  30 in total

Review 1.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

Review 2.  Adaptive Immune Responses in Hepatitis A Virus and Hepatitis E Virus Infections.

Authors:  Christopher M Walker
Journal:  Cold Spring Harb Perspect Med       Date:  2019-09-03       Impact factor: 6.915

3.  Antiviral Candidates for Treating Hepatitis E Virus Infection.

Authors:  Natalie E Netzler; Daniel Enosi Tuipulotu; Subhash G Vasudevan; Jason M Mackenzie; Peter A White
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

4.  Pan-Genotype Hepatitis E Virus Replication in Stem Cell-Derived Hepatocellular Systems.

Authors:  Xianfang Wu; Viet Loan Dao Thi; Peng Liu; Constantin N Takacs; Kuanhui Xiang; Linda Andrus; Jérôme Gouttenoire; Darius Moradpour; Charles M Rice
Journal:  Gastroenterology       Date:  2017-12-24       Impact factor: 22.682

Review 5.  Stem Cell-Derived Culture Models of Hepatitis E Virus Infection.

Authors:  Viet Loan Dao Thi; Xianfang Wu; Charles M Rice
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

Review 6.  Innate Immunity to Enteric Hepatitis Viruses.

Authors:  Zongdi Feng; Stanley M Lemon
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

7.  ISG15 Modulates Type I Interferon Signaling and the Antiviral Response during Hepatitis E Virus Replication.

Authors:  Harini Sooryanarain; Adam J Rogers; Dianjun Cao; Mary Etna R Haac; Yogesh A Karpe; Xiang-Jin Meng
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

8.  Differential Inhibition of HIV Replication by the 12 Interferon Alpha Subtypes.

Authors:  Armando Espinosa Ortiz; Olivia Blake; Alexandra Tauzin; Calaiselvy Soundaramourty; Charles Joly-Beauparlant; Alexandre Nicolas; Arnaud Droit; Jacques Dutrieux; Jérôme Estaquier; Fabrizio Mammano
Journal:  J Virol       Date:  2021-07-12       Impact factor: 5.103

9.  Resolution of hepatitis E virus infection in CD8+ T cell-depleted rhesus macaques.

Authors:  William Bremer; Heather Blasczyk; Xin Yin; Eduardo Salinas; Arash Grakoui; Zongdi Feng; Christopher Walker
Journal:  J Hepatol       Date:  2021-05-04       Impact factor: 30.083

Review 10.  Mutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing Mutations.

Authors:  Daniel Todt; Stephanie Walter; Richard J P Brown; Eike Steinmann
Journal:  Viruses       Date:  2016-10-13       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.